Ikena Oncology (NASDAQ:IKNA) Receives “Neutral” Rating from Wedbush

Ikena Oncology (NASDAQ:IKNA)‘s stock had its “neutral” rating reiterated by analysts at Wedbush in a research report issued to clients and investors on Monday,RTT News reports. They currently have a $2.00 price objective on the stock. Wedbush’s target price suggests a potential upside of 19.76% from the stock’s current price.

Separately, HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of Ikena Oncology in a research report on Monday, November 11th.

Ikena Oncology Trading Up 7.7 %

Ikena Oncology stock traded up $0.12 during midday trading on Monday, hitting $1.67. 5,144,815 shares of the stock were exchanged, compared to its average volume of 250,165. The stock’s 50-day simple moving average is $1.69 and its 200 day simple moving average is $1.69. Ikena Oncology has a fifty-two week low of $1.22 and a fifty-two week high of $2.29. The stock has a market capitalization of $80.59 million, a price-to-earnings ratio of -1.36 and a beta of 0.49.

Ikena Oncology (NASDAQ:IKNA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.08. Equities analysts anticipate that Ikena Oncology will post -0.91 EPS for the current fiscal year.

Institutional Trading of Ikena Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IKNA. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Ikena Oncology during the second quarter worth about $30,000. BBR Partners LLC acquired a new stake in Ikena Oncology during the 2nd quarter worth approximately $33,000. AQR Capital Management LLC purchased a new position in Ikena Oncology in the 2nd quarter valued at approximately $36,000. FMR LLC grew its stake in shares of Ikena Oncology by 94.1% in the third quarter. FMR LLC now owns 38,374 shares of the company’s stock worth $66,000 after acquiring an additional 18,607 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Ikena Oncology during the second quarter worth $75,000. Hedge funds and other institutional investors own 75.00% of the company’s stock.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.